Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,494 active trials253 approved drugs3,567 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics477
Variants & evidence3567
Drugs398
Trials92594
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,275)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,801–3,825 of 4,275 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
· Cancer Res · 2009 · PMID 19318574 · validated civic_curation pubmed
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
· Proc Natl Acad Sci U S A · 2012 · PMID 22550175 · validated civic_curation pubmed
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
· Clin Cancer Res · 2015 · PMID 25351743 · validated civic_curation pubmed
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
· Nat Chem Biol · 2015 · PMID 26167872 · validated civic_curation pubmed
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
· Cancer Res · 2010 · PMID 20179196 · validated civic_curation pubmed
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.
· Cancer Res · 2009 · PMID 19723655 · validated civic_curation pubmed
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
· Nature · 2012 · PMID 22425996 · validated civic_curation pubmed

Showing 3,801–3,825 of 4,275 publications

← Previous
1
…
152
153
154
…
171
Next →

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis.

· Genet Mol Res · 2015 · PMID 26662432 · validated civic_curation pubmed

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

· Clin Cancer Res · 2012 · PMID 22038994 · validated civic_curation pubmed

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

· Cancer Biol Ther · 2016 · PMID 26574622 · validated civic_curation pubmed

Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.

· Clin Cancer Res · 2015 · PMID 26179511 · validated civic_curation pubmed

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

· Proc Natl Acad Sci U S A · 2015 · PMID 26372962 · validated civic_curation pubmed

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

· Proc Natl Acad Sci U S A · 2015 · PMID 25733882 · validated civic_curation pubmed

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

· Clin Cancer Res · 2005 · PMID 16243825 · validated civic_curation pubmed

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

· Cancer Res · 2008 · PMID 18757403 · validated civic_curation pubmed

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

· Sci Rep · 2016 · PMID 26786851 · validated civic_curation pubmed

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.

· Oncotarget · 2016 · PMID 27049722 · validated civic_curation pubmed

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

· Cancer Discov · 2013 · PMID 23619167 · validated civic_curation pubmed

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

· Pigment Cell Melanoma Res · 2014 · PMID 24495407 · validated civic_curation pubmed

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

· Clin Cancer Res · 2011 · PMID 21278246 · validated civic_curation pubmed

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.

· Genes Dev · 2012 · PMID 22802530 · validated civic_curation pubmed

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

· Nature · 2012 · PMID 22281684 · validated civic_curation pubmed

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

· Clin Cancer Res · 2013 · PMID 23549875 · validated civic_curation pubmed

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

· Cancer Cell · 2004 · PMID 15324695 · validated civic_curation pubmed